Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens

OBJECTIVE: CYP2C19 metabolic activity influences the efficacy of Helicobacter pylori eradication therapies comprising PPIs. Rabeprazole (RPZ) and esomeprazole (EPZ) are PPIs not extensively metabolized by CYP2C19. The aim of this study was to elucidate whether or not first-line triple therapies usin...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Intern Med
Auteurs principaux: Shimoyama, Tadashi, Chinda, Daisuke, Sawada, Yoshihiko, Komai, Kazuo, Chiba, Hironobu, Saito, Yoshiharu, Sasaki, Yoshio, Matsuzaka, Masashi, Fukuda, Shinsaku
Format: Artigo
Langue:Inglês
Publié: The Japanese Society of Internal Medicine 2017
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519461/
https://ncbi.nlm.nih.gov/pubmed/28674348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.56.7823
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires